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Purpose: This study develops a tracer kinetic model of xenon uptake in the human 
brain to determine the transfer rate of inhaled hyperpolarized 129Xe from cerebral 
blood to gray matter that accounts for the effects of cerebral physiology, perfusion 
and magnetization dynamics. The 129Xe transfer rate is expressed using a tracer 
transfer coefficient, which estimates the quantity of hyperpolarized 129Xe dissolved 
in cerebral blood under exchange with depolarized 129Xe dissolved in gray matter 
under equilibrium of concentration.
Theory and Methods: Time-resolved MR spectra of hyperpolarized 129Xe dissolved 
in the human brain were acquired from three healthy volunteers. Acquired spectra 
were numerically fitted with five Lorentzian peaks in accordance with known 129Xe 
brain spectral peaks. The signal dynamics of spectral peaks for gray matter and red 
blood cells were quantified, and correction for the 129Xe T1 dependence upon blood 
oxygenation was applied. 129Xe transfer dynamics determined from the ratio of the 
peaks for gray matter and red blood cells was numerically fitted with the developed 
tracer kinetic model.
Results: For all the acquired NMR spectra, the developed tracer kinetic model fitted 
the data with tracer transfer coefficients between 0.1 and 0.14.
Conclusion: In this study, a tracer kinetic model was developed and validated that 
estimates the transfer rate of HP 129Xe from cerebral blood to gray matter in the 
human brain.
K E Y W O R D S
blood-brain barrier, gas-exchange, hyperpolarized xenon-129, time-resolved magnetic resonance 
spectroscopy, tracer kinetic model
1 |  INTRODUCTION
The blood-brain barrier (BBB) separates the intravascular 
space from the brain parenchyma, and is formed by spe-
cialized endothelial cells held together by tight junctions, 
covered by basal lamina and surrounded by pericytes, as 
shown in Figure 1. It acts as a selectively permeable bar-
rier, which allows molecules essential for brain function 
through the barrier, while restricting the passage of noxious 
or neuroactive substances, and is vital for maintaining normal 
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neuronal function.1 The consequence of a ruptured BBB is 
irregular transportation (and clearance) of gases, nutrients, 
water and other essential molecules across the barrier. These 
pathophysiological irregularities of an impaired BBB can 
be diagnostically assigned to various diseases processes,2-6 
typically by observing the movement of a tracer across the 
barrier. However, dysfunction of an intact BBB can also 
occur due to prolonged oxidative stress, causing deposition 
of plaque (example amyloid β),7-9 build-up of lipids, decline 
of pericytes,10 cognitive ability and brain function.11 This 
can occur even before the barrier becomes leaky or ruptured. 
For diagnosis, the two most commonly used tracers are io-
dinated contrast agent for X-ray CT and gadolinium chelated 
contrast agent for dynamic contrast enhanced MRI,12-16 nei-
ther of which cross an intact BBB, but are able to when it 
is leaky or ruptured. The arterial spin labeling (ASL) based 
MRI technique17-21 images magnetically tagged water mole-
cules in the arterial blood delivered to brain tissue. Since the 
water molecules cross the intact BBB, this technique is being 
investigated for diagnosis of BBB diseases.22-24 Nevertheless, 
the technique has some limitations due to acquisition strat-
egy (post labeling delay time, labeling plane) competing with 
physiology (longitudinal relaxation time, arterial transit time) 
and abundance of water molecules in the brain tissue (back-
ground noise, magnetization transfer).19,25
Xenon is an exogenous tracer that passively crosses the 
intact BBB.1 Recently, hyperpolarized (HP) xenon-129 has 
been demonstrated as an agent to image the uptake of in-
haled gas into human brain tissue after crossing the intact 
BBB26,27 by MRI, and the method has been shown to be 
repeatable.28 Preliminary clinical investigations of HP 129Xe 
brain MRI have shown novel and complementary image con-
trast for stroke,29 Alzheimer’s disease30 and functional brain 
imaging.31 HP 129Xe dissolved in the brain exhibits discrete 
chemical shifts for various biochemical compartments such 
as cerebral red blood cells (RBC), cerebrospinal/interstitial 
fluid, gray matter, white matter and soft muscular fat.27 The 
image signal-to-noise ratio (SNR) and contrast is weighted by 
regional cerebral perfusion, physiology (tissue compartmen-
tal volumes, temperature, blood pressure) and gas-transfer 
from cerebral blood to gray matter across the BBB,26 while 
the magnetization history of the HP 129Xe during its journey 
through these compartments is also factorial.
The transfer dynamics of HP 129Xe, a passive tracer, is 
not influenced by regional cellular metabolism, oxygen 
extraction32 or electrolytic balance. Thus, HP 129Xe MRI 
potentially holds unique information about the BBB by 
characterizing the passive transferability across the barrier. 
Nevertheless, this is influenced by the effects of regional 
brain physiology and perfusion. The HP aspect of the tracer 
adds further challenges as the MR detection is limited to the 
HP pool of 129Xe,33 but the gas transfer (membrane diffusion) 
dynamics are influenced by the concentration of all 129Xe 
atoms in the respective compartments, some of which may 
not be HP and therefore are undetectable.
This study develops a tracer kinetic model to determine 
the transfer rate of HP 129Xe from the cerebral blood to gray 
matter by considering the mass transfer of 129Xe irrespective 
of its status of hyperpolarization, with the aim of quantita-
tively measuring the compartmental transfer dynamics in 
F I G U R E  1  Illustration of BBB, cerebral blood volume for gray matter, gray matter volume, arterial blood volume and transfer of xenon 
across the barrier
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order to characterize the BBB function. In contrast to earlier 
mathematical modeling studies of 129Xe uptake in brain tis-
sue that arrived at the concentration of 129Xe over time du-
ration,34-36 the model presented here uses the concentrations 
of 129Xe in cerebral blood and gray matter compartments 
measured using NMR spectroscopy to estimate the transfer 
dynamics between them. The proposed model also considers 
the variation in longitudinal relaxation of HP 129Xe dissolved 
in the blood by monitoring the variation in oxygenation- 
dependent chemical shift of RBC spectral peak.
2 |  THEORY
2.1 | Tracer kinetic model for HP 129Xe 
uptake in the brain
After inhalation of HP 129Xe, it crosses the alveolar-capillary 
barrier and is transported to the brain through the systemic 
circulation in approximately 4 s.37 In the brain, 129Xe crosses 
the intact BBB passively in to the brain parenchyma,1 and 
thereafter is under continuous diffusional exchange across 
the barrier. The cerebral blood volume of ~4 mL for 100 g 
of gray matter37-39 and cerebral capillary of radius 2.5~4 
µm40-43 implies that the radius of the gray matter coaxial with 
the capillary and mean distance between capillaries would 
be 12.5~20 µm and 25~40 µm40-43 respectively, as shown 
in Figure 1. As the diffusion coefficient of xenon dissolved 
in the cerebral blood or gray matter has not been character-
ized, it can be approximated by using the diffusion coeffi-
cient dissolved in water of ~1 × 10−5 cm2 s−1.44 Under these 
conditions, a 95% equilibrium of concentration of 129Xe be-
tween cerebral blood and gray matter is reached in 0.2~0.4 
seconds.45 Hence, the NMR spectral peaks in time-resolved 
spectra that are acquired using a sequence repetition time 
(TR), that is longer than both the cerebral mean transit time 
(≈3.3 s39,46,47) and equilibrium time (0.4 s), are linearly pro-
portional to the concentration in the respective biochemical 
compartments.
Consider time-resolved NMR spectroscopic acquisitions 
where each acquisition consists of a RF excitation pulse and 
subsequent saturation pulses. After every acquisition the bulk 
magnetization of HP 129Xe is depolarized (DP) to thermal 
equilibrium such that the NMR signal from further excitation 
of this pool of 129Xe in the brain is too weak to be detectable. 
Therefore, in each of the acquired time-resolved spectra, the 
spectral peaks do not represent the total quantity; instead, 
they represent the quantity of HP 129Xe accumulated between 
two consecutive NMR acquisitions. Nevertheless, there is 
continuous accumulation of DP 129Xe in the brain. Due to 
their respective discrete chemical shifts,27 the change in the 
relative concentration of HP 129Xe in cerebral blood and gray 
matter can be monitored over time, and thus HP 129Xe can be 
used as a tracer to examine the transfer dynamics across the 
shared barrier. Because there is a continuous arterial in-flow 
of HP 129Xe to the cerebral vasculature, the forward trans-
fer (TF) of 
129Xe from cerebral blood to gray matter is HP 
129Xe and therefore is detectable, annotated as TF in Figure 1. 
We define the TF rate as the quantity of HP 
129Xe delivered 
to gray matter in the time duration (TR) between two suc-
cessive acquisitions, considering both arterial in-flow of HP 
129Xe and diffusional gas-exchange across the BBB. Due to 
the radiofrequency (RF) saturation pulses used after each ac-
quisition, the backward transfer of 129Xe from gray matter 
to cerebral blood is DP 129Xe and therefore is undetectable, 
annotated as TB in Figure 1. NMR detection depends on the 
magnetization (M), which is proportional to the quantity (Q) 
and polarization of 129Xe, whereas the transfer dynamics 
depends on concentration (C), which is proportional to the 
quantity irrespective of its status of polarization.
For a given cerebral blood flow for gray matter F, parti-
tion coefficient of xenon between gray matter and blood λ, 
cerebral mean transit time ψ, cerebral blood volume VBlood 
per volume of gray matter VGM, concentration of HP 
129Xe in 
arterial blood CA and NMR spectral repetition time tTR, using 
Fick’s principle developed for an inert gas tracer by Kety,45 
we can arrive at the concentration of 129Xe in gray matter 
CGM for the time instance immediately after the (n−1)
th RF 
acquisition as shown in Equation (1); nevertheless, this pool 


















. The quantities of HP (QGM,HP) and DP 
(QGM,DP) 
129Xe in the gray matter at the time instance at the 
n
th RF acquisition are:
Such that, the total quantity of xenon is 
QGM = QGM,HP + QGM,DP. Between the time instances of the 
(n − 1) th and nth RF acquisition, there is continuous diffu-
sional exchange of 129Xe between gray matter and cerebral 
blood. If we let r be the fraction of 129Xe in gray matter 
that would exchange with 129Xe in cerebral blood, we have 
QGM = (1 − r )QGM + rQGM, where rQGM is the quantity 
of 129Xe that would exchange with cerebral blood. Further, 
 because we have two pools of 129Xe (HP and DP) in both gray 
matter and cerebral blood, for the fraction of 129Xe that would 
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exchange: (i) HP 129Xe being replaced by HP 129Xe QGM,HP↔HP, 
(ii) HP 129Xe being replaced by DP 129Xe QGM,HP↔DP, (iii) 
DP 129Xe being replaced by DP 129Xe QGM,DP↔DP, and (iv) 
DP 129Xe being replaced by HP 129Xe QGM,DP↔HP. Letting k1 
and k
2
 be the factors that determine the fraction of 129Xe of a 
particular pool being replaced by the same pool, we can then 
derive the six-term expression;
The factors (1−k1 ) and (1 − k2 ) are the tracer transfer 
constants that determine the fraction of one pool of 129Xe 
being replaced by the other pool. For simplicity of calcula-
tion in the current context, we use; k= k1 = k2. In Equation 
(3), only the first, third and last term relate to HP 129Xe which 
contributes to the NMR signal, thus rewriting and substitut-
ing from Equation (2), we have;
Equation (4) assumes that the gray matter compartment is 
solely in exchange with the cerebral blood compartment, and 
vice versa. The factor r that determines the fraction of 129Xe 
that would exchange with cerebral blood depends on several 
factors such as the capillary diameter, the mean distance be-
tween capillaries and the diffusivity of 129Xe. Consider the 
diffusivity of 129Xe in water D = 1 × 103 µm2s−1 and the 
mean diffusive displacement from gray matter volume to 
cerebral blood volume dGM → Blood ≈ 12.5 ~ 20 µm from 





 for diffusion from 
gray matter to cerebral blood volume is approximately;
Thus, the factor r can be approximated as;










Blood,HP is the concentra-
tion of HP 129Xe in cerebral blood. Rearranging and integrat-
ing for the time interval t
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Similarly, for the quantity of HP 129Xe in arterial blood 
Q
A,HP, QA,HP = CAVA, where VA is the arterial blood volume 
between the lungs and the brain.
To corroborate tracer kinetics with the detected NMR 
spectroscopy, let M0 be the bulk magnetization, such that 
M0 ≈ QPΦ, where Q is the quantity of 
129Xe and Φ depends 
on gyromagnetic ratio, reduced Planck’s constant and nuclear 
spin quantum number.48P is the polarization of the sample, 
such that PHP and PDP are the polarization of the HP pool of 
129Xe that is detectable and DP pool of 129Xe that is not de-
tectable respectively. The magnetization in transverse plane 
is propositional to M0, weighted by flip angle and transverse 
relaxation time (T∗
2
). For a 90° flip angle, the acquired NMR 





2 , where f0 is the center fre-
quency of the spectral peak. The corresponding Fourier trans-
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 is the half power peak width. Further, integrating the spec-
trum, we have M0 ∫
∞
−∞
L {, f} = M0, and thus, the magni-




) measures the quantity 
(QGM, QBlood) of 
129Xe for a given polarization. PDP depends 
on the strength of the static magnetic field, Boltzmann’s 
constant, gyromagnetic ratio, reduced Planck’s constant 
and temperature of 129Xe.48PHP depends on the polarization 
achieved by the spin-exchange optical pumping process and 
PHP ≈ PDP10
5.33 The polarization (PHP ) decays by longitu-
dinal relaxation in several distinct biochemical compartments 
on its journey to the brain; in the gas-phase in the lungs T1GAS, 
in the dissolved-phase in the blood T1Blood,L→B during the lung-
to-brain (L → B) transit time L→B and in the dissolved-phase 
in the gray matter T1GM during the TR ( tTR ). Considering the 
decay of polarization, for a detectable NMR spectral peak at 
the nth acquisition, we have the longitudinal magnetization as:
where, b
RBC
 is a scalar factor determining the quantity of 
129Xe in the RBCs in the whole of the head when compared 
to the total quantity of 129Xe in cerebral blood that is in ex-
change with gray matter. Γ is a factor defining the dynamics 
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alveolar-capillary barrier and the relative volumes/pressure 
of alveoli and Pulmonary capillaries. Considering the ratio of 
M
GM
 by MBlood and rearranging the terms, we have:
Equation (7) is the tracer kinetic model for transfer dy-
namics of HP 129Xe in the brain and is the estimate of the 
forward transfer TF rate in Figure 1.The transfer dynamic 
is independent of Q
A,NMR and the term in the brackets in 
Equation (7) is a constant. Although −
tTR
T1Blood
 is independent 
of time, T1Blood varies with the oxygenation of cerebral blood. 
Nevertheless, this dependence of T1Blood is well established in 
the literature and the chemical shift of the RBC spectral peak 
can be used to monitor variations in blood oxygenation and 
apply a T1 correction accordingly.
32,50-52 Table 1 provides a 
list of the various parameters used in the study.
3 |  METHODS
In vivo MR brain spectroscopy with 129Xe was performed 
with approval from the UK National Research Ethics 
Committee. Spectroscopic experiments were conducted on 
three healthy male volunteers aged 25 y, 33 y and 34 y, and 
repeated three times for each of the volunteers. The heart rate 
and SO2 were monitored throughout the breath hold, which 
lasted no more than 24 s.
Experiments were performed on a GE HDx 1.5 T clinical 
MRI scanner. 129Xe gas was HP to PHP > 30% polarization 
using a POLARIS (Sheffield, UK) regulatory approved spin 
exchange optical pumping polarizer.53 HP 129Xe gas of 500 
mL was mixed with N
2
 for a total inhaled dose of 1 L. An 
eight-leg band-pass birdcage RF coil was used27 for trans-
ceiver; with inner diameter of 300 mm and length of 295 
mm. The gas mixture was administered by inhalation from a 
Tedlar bag as described in Rao et al.26 Time-resolved whole-
brain spectra were acquired during a breath-hold, so that the 
HP 129Xe gas mixture was maintained as a reservoir in the 
lungs supplying the dissolved 129Xe plasma and RBC signal 
to the brain through alveolar-capillary gas exchange and on-
ward through the systemic circulation.
MR spectroscopy parameters were as follows: center fre-
quency = 17660800 Hz (198 ppm downfield from the 129Xe 
gas phase resonance), flip angle = 90°, non-selective RF 
hard-pulse with duration of 500 µs, receiver bandwidth = 
1.2 kHz and number of sample points = 128. The acquisition 
time was ~107 ms, much longer than T∗
2
 of 129Xe in RBC 
(2 ms54) and gray matter (8.8 ms27). TR was set to 4 s, which 
is longer than the typical cerebral mean transit time (Ψ ) of 
3.3 s39,46,47 and the equilibrium time of 0.4 s,45 assuming Ψ 
will not increase by more than 20% during the breath-hold.55 
Acquisition of time-resolved spectra was initiated immedi-
ately after the inhalation of the gas dose with two cycles of 
non-selective 90° RF pulses to destroy the polarization of the 
initial unknown quantity of HP 129Xe in the brain. After each 
subsequent pulse-acquire NMR spectroscopic acquisition, 
two non-selective 90° RF pulses were applied to destroy the 
polarization of the residual HP 129Xe.
A summation of five complex Lorentzian peaks in accor-
dance with the known five spectral peaks of 129Xe dissolved 
in the human head27,36 was numerically fitted to the acquired 
NMR spectra, and each of the spectral peaks were quantified as 

























Parameter Symbol Value Reference
Cerebral blood volume for 100 g of gray matter VGM VBlood ~4 mL
37-39
Radius of cerebral capillaries ‒ 2.5 ~ 4 µm 40-43
Mean distance between capillaries ‒ 25 ~ 40 µm 40-43
Diffusion coefficient of 129Xe dissolved in water D 1 × 103µm2 s−1 44
Time to reach 95% equilibrium in concentration ‒ 0.2 ~ 0.4 s 45
129Xe Partition coefficient gray matter/blood λ 0.88 56
Cerebral mean transit time ψ 3.3 s 39,46,47
Longitudinal relaxation of 129Xe in blood T1Blood 4.5 s
32,50-52
Transverse relaxation of 129Xe in blood ‒ 2 ms 54
Transverse relaxation of 129Xe in gray matter ‒ 8.8 ms 27
Factor r r 1 This study
129Xe displacement time tGM→Blood 75 ~ 200 ms This study
Repetition Time (TR) tTR 4 s This study
T A B L E  1  List of key parameters used for the tracer kinetic model and analysis
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spectral peaks represent the bulk magnetization of HP 129Xe in 
corresponding compartments, namely M
GM
 and MBlood for gray 
matter and cerebral RBC compartments, respectively.
The transfer dynamics of HP 129Xe between gray matter 
and cerebral blood was determined by evaluating the ratio of 
the time course of the spectral peaks of 129Xe in gray matter 





). Using typical physiological 
values; cerebral blood volume for gray matter of 4 mL per 
100 g of tissue,37-39 cerebral mean transit time of 3.3 s39,46,47 
and the partition coefficient for xenon dissolved in gray mat-
ter to blood as 0.8856 (see Table 1); the tracer kinetic model 
in Equation (7) was rescaled and numerically fitted to the 
acquired transfer dynamics using a range of tracer transfer 
constants (1 − k ) = 0 to 1. The error in the numerical fit was 
calculated as the standard deviation of the difference between 
the tracer kinetic model from Equation (7) and the acquired 
transfer dynamic ratio, expressed as a percentage by normal-
izing by the mean value of the acquired transfer dynamic 
ratio.
4 |  RESULTS
A typical series of time-resolved spectra acquired from the 
head of the 34-y-old male volunteer is shown in Figure 2A. 
Summation of five complex Lorentzian peaks fitted to the 
acquired spectrum in Figure 2A is shown in Figure 2B. The 
time course of the individual spectral peaks of HP 129Xe dis-
solved in cerebral RBC and gray matter is shown in Figure 
2C and D, respectively.
Quantification of the spectral peaks for cerebral blood and 
gray matter is shown in Figure 3A along with the time course 
of the individual quantified spectral peaks. The chemical 
shifts of both individual spectral peaks over the time-course 
of the acquisition are shown in Figure 3B. Variation in chem-
ical shift can be observed for the cerebral RBC peak. This 
indicates underlying variations in the oxygenation of cerebral 
blood and is used to determine the variation in T1 associated 
with it. The time courses of both quantified individual spec-
tral peaks are shown in Figure 3C. Figure 3C also shows the 
correction to the quantification of the cerebral RBC peak for 
variation in T1 of 
129Xe in the RBCs derived using the varia-
tion in chemical shift from Figure 3B.
The transfer dynamics of HP 129Xe between gray matter and 
cerebral blood is shown in Figure 4A, both with and without the 
correction for cerebral blood oxygenation applied to the RBC 
peak, along with the rescaled and fitted tracer kinetic model 
from Equation (7) for the tracer transfer constant (1 − k ) = 0.12
. Extrapolation of the model to the case of steady-state xenon 
tissue saturation is shown in Figure 4B, and indicates that the 
forward transfer (TF) rate of HP 
129Xe reaches 95% saturation 
after approximately 200 s. The transfer dynamics of HP 129Xe 
F I G U R E  2  A, Acquired spectra for volunteer 34 y old, male. B, Artificially generated spectra comprising five complex Lorentzian peaks to 
numerically fit the acquired spectra in (A). Artificially generated complex Lorentzian peak for cerebral red blood cells (C) and gray matter (D)
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between gray matter and cerebral blood for all the three volun-
teers for all the three repeats are shown in Figure 5.
For each of the acquisitions, the transfer dynamics with 
and without the correction for blood oxygenation, along 
with the variation in chemical shift of 129Xe in RBCs and the 
numerical fit of the tracer kinetic model in Equation (7) are 
shown. The developed tracer kinetic model returned values 
for the tracer transfer constant between 0.1 and 0.14 over the 
three volunteers. The error in the numerical fit was between 
2.3% and 4.2% as indicated in Figure 5.
F I G U R E  3  A, Illustration of the quantification and time course of spectral peaks for red blood cells and gray matter. Projection on Time-
chemical shift plane – time course of the peak location of both spectral peaks. Projection on Time-NMR unit plane – time course of both quantified 
spectral peaks. Note: although peaks were quantified as the product of π, height and width of the peak, only the product of height and width of the 
peak is shown here for ease of illustration. B, Variation in chemical shift for both peaks; cerebral red blood cells and gray matter. C, Time course 
of spectral peaks from gray matter and cerebral red blood cells, with and without correction of the RBC peak for variation in T1 due to blood 
oxygenation, derived using the variation in chemical shift in (B)
8 |   RAO ET AL.
5 |  DISCUSSION
The unique aspects of the proposed MR spectroscopy tech-
nique based on a tracer kinetic model are as follows; First, 
the dynamics of the relative quantity of 129Xe is quantified 
using spectral peaks separated by their distinct chemical 
shifts, avoiding potential uncertainties related to non-spe-
cific binding and partial volume estimates for gray matter 
and blood which appear to vary with disease progression 
and aging in the brain.13,57-60 Second, the NMR signal from 
the tracer (HP 129Xe) once detected after RF excitation be-
comes NMR invisible (DP), enabling the observation of 
the physiological dynamics of cerebral uptake and diffu-
sional exchange.
An interesting observation of the model is that it pre-








Equation 7) increases until saturation. This is because, over 
time, DP 129Xe accumulates in the gray matter that will 
diffuse back (backward transferTB) in to cerebral blood and 
displace an equal amount of HP 129Xe (forward transferT
F
) 
from cerebral blood to gray matter. This exchange oc-
curs without disrupting the equilibrium in concentration 
of overall 129Xe (irrespective of its status of polarization) 
between the two compartments. In addition, due to con-
tinuous arterial blood flow carrying fresh HP 129Xe to the 
head, the concentration of DP 129Xe in cerebral blood is 
much lower than that of gray matter increasing the like-
lihood of DP 129Xe in gray matter being replaced by HP 
129Xe. Extrapolation of the model to 200 s and beyond in-


























tion n =∞. Nevertheless, this saturation time does not have 
physiological interpretation in the current context.
The factors k1 and k2 may not be equal, and estimating 
these factors individually and their inter-relationship is the 
scope of future study. The key limitations of the model are 
that the spectral measurements are performed over the whole 
brain, and thus average values are considered for cerebral 
blood flow, cerebral blood volume, mean transit time and 
gray matter volume. Using spatially resolved spectroscopy 
and for a known regional mean transit time and cerebral 
blood volume for gray matter, that can be estimated from 
1H MRI for example,61 the proposed tracer kinetic model 
estimates the regional efficacy of 129Xe transfer or uptake 
across the intact BBB. This might provide additional use-
ful insight in to the underlying regional pathophysiology, 
such as BBB surface area and intact-barrier permeability/
transferability changes. An in depth clinical investigation 
of the method in this aspect is the scope of future work. 
Also, if the mean transit time is known a priori, the NMR 
pulse repetition time can be optimized. Uncertainty in the 
estimation can be attributed to errors in the numerical 
fit of the spectra, which in turn can be attributed to the 
achieved SNR. Future studies will be aided by increases 
in the signal-to-noise ratio of the spectra, for example by 
using high-sensitivity radio frequency coils26 and improved 
polarization of 129Xe gas,53 and these improvements will 
hopefully facilitate a time-resolved spectroscopic imaging 
implementation of the global spectroscopy concept pro-
posed here.
F I G U R E  4  A, Transfer dynamics of 129Xe between cerebral blood and gray matter, with and without correction of the RBC peak (see Figure 
3C), along with a rescaled and fitted tracer kinetic model (from Equation 7) with a tracer transfer constant (1−k) = 0.12. Error bars calculated 
considering three repetitions. B, Extrapolation of the tracer kinetic model to illustrate that the forward transfer (TF) rate of HP 
129Xe reaches 95% 
saturation at approximately 200 s
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6 |  CONCLUSIONS
In this study, we developed a tracer kinetic model for time-
resolved NMR spectra of HP 129Xe in the human brain to esti-
mate the transfer rate of HP 129Xe from cerebral blood to gray 
matter that depends on a tracer transfer constant for a known 
mean transit time and cerebral blood volume for gray mat-
ter. We believe this model will enable further studies to de-
termine regional 129Xe tracer transfer constants with a focus 
of gaining insight into the pathophysiology of the BBB in 
diseases such as intact-barrier edema, arterial plaque, inflam-
mation, infarct following stroke and to aid the assessment of 
drug delivery to the brain. In addition, in light of the passive 
nature of the xenon tracer, it could serve as a cross-reference 
for studies involving oxygen, water or glucose uptake, which 
are driven by metabolism and/or electrolytic balance.
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